First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Create your
podcast in
minutes
It is Free